Percutaneous cervical cordotomy for cancer-related pain: national data

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

StandardStandard

Percutaneous cervical cordotomy for cancer-related pain: national data. / INPIC Group.
Yn: BMJ Supportive and Palliative Care, Cyfrol 10, Rhif 4, 12.2020, t. 429-434.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

HarvardHarvard

INPIC Group 2020, 'Percutaneous cervical cordotomy for cancer-related pain: national data', BMJ Supportive and Palliative Care, cyfrol. 10, rhif 4, tt. 429-434. https://doi.org/10.1136/bmjspcare-2019-002057

APA

CBE

MLA

VancouverVancouver

INPIC Group. Percutaneous cervical cordotomy for cancer-related pain: national data. BMJ Supportive and Palliative Care. 2020 Rhag;10(4):429-434. Epub 2020 Maw 27. doi: 10.1136/bmjspcare-2019-002057

Author

INPIC Group. / Percutaneous cervical cordotomy for cancer-related pain : national data. Yn: BMJ Supportive and Palliative Care. 2020 ; Cyfrol 10, Rhif 4. tt. 429-434.

RIS

TY - JOUR

T1 - Percutaneous cervical cordotomy for cancer-related pain

T2 - national data

AU - INPIC Group

AU - Poolman, Marlise

AU - Makin, Matthew

AU - Briggs, Jess

AU - Scofield, Kate

AU - Campkin, Nick

AU - Williams, Michael

AU - Sharma, Manohar Lal

AU - Laird, Barry

AU - Mayland, Catriona R

N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

PY - 2020/12

Y1 - 2020/12

N2 - OBJECTIVES: Percutaneous cervical cordotomy (PCC) is an interventional ablative procedure in the armamentarium for cancer pain treatment, but there is limited evidence to support its use. This study aimed to assess the effectiveness and safety of PCC.METHODS: Analysis was undertaken of the first national (UK) prospective data repository of adult patients with cancer undergoing PCC for pain treatment. The relationship between pain and other outcomes before and after PCC was examined using appropriate statistical methods.RESULTS: Data on 159 patients' PCCs (performed from 1 January 2012 to 6 June 2017 in three centres) were assessed: median (IQR) age was 66 (58-71) years, 47 (30%) were female. Mesothelioma was the most common primary malignancy (57%). The median (IQR) time from cancer diagnosis to PCC assessment was 13.3 (6.2-23.2) months; PCC to follow-up was 9 (8-25) days; and survival after PCC was 1.3 (0.6-2.8) months. The mean (SD) for 'average pain' using a numerical rating scale was 6 (2) before PCC and 2 (2) at follow-up, and for 'worst pain' 9 (1) and 3 (3), respectively. The median (IQR) reduction in strong opioid dose at follow-up was 50% (34-50). With the exception of 'activity', all health-related quality of life scores (5-level version of EuroQol-5 Dimension) either improved or were stable after PCC. Six patients (4%) had PCC-related adverse events.CONCLUSIONS: PCC is an effective treatment for cancer pain; however, findings in this study suggest PCC referrals tended to be late in patients' disease trajectories. Further study into earlier treatment and seeking international consensus on PCC outcomes will further enhance opportunities to improve patient care.

AB - OBJECTIVES: Percutaneous cervical cordotomy (PCC) is an interventional ablative procedure in the armamentarium for cancer pain treatment, but there is limited evidence to support its use. This study aimed to assess the effectiveness and safety of PCC.METHODS: Analysis was undertaken of the first national (UK) prospective data repository of adult patients with cancer undergoing PCC for pain treatment. The relationship between pain and other outcomes before and after PCC was examined using appropriate statistical methods.RESULTS: Data on 159 patients' PCCs (performed from 1 January 2012 to 6 June 2017 in three centres) were assessed: median (IQR) age was 66 (58-71) years, 47 (30%) were female. Mesothelioma was the most common primary malignancy (57%). The median (IQR) time from cancer diagnosis to PCC assessment was 13.3 (6.2-23.2) months; PCC to follow-up was 9 (8-25) days; and survival after PCC was 1.3 (0.6-2.8) months. The mean (SD) for 'average pain' using a numerical rating scale was 6 (2) before PCC and 2 (2) at follow-up, and for 'worst pain' 9 (1) and 3 (3), respectively. The median (IQR) reduction in strong opioid dose at follow-up was 50% (34-50). With the exception of 'activity', all health-related quality of life scores (5-level version of EuroQol-5 Dimension) either improved or were stable after PCC. Six patients (4%) had PCC-related adverse events.CONCLUSIONS: PCC is an effective treatment for cancer pain; however, findings in this study suggest PCC referrals tended to be late in patients' disease trajectories. Further study into earlier treatment and seeking international consensus on PCC outcomes will further enhance opportunities to improve patient care.

KW - Aged

KW - Cancer Pain/surgery

KW - Cervical Vertebrae/surgery

KW - Cordotomy/methods

KW - Female

KW - Humans

KW - Male

KW - Mesothelioma/complications

KW - Middle Aged

KW - Minimally Invasive Surgical Procedures/methods

KW - Pain Management

KW - Pain Measurement

KW - Prospective Studies

KW - Quality of Life

KW - Spinal Cord/surgery

KW - Time-to-Treatment

KW - Treatment Outcome

U2 - 10.1136/bmjspcare-2019-002057

DO - 10.1136/bmjspcare-2019-002057

M3 - Article

C2 - 32220943

VL - 10

SP - 429

EP - 434

JO - BMJ Supportive and Palliative Care

JF - BMJ Supportive and Palliative Care

SN - 2045-435X

IS - 4

ER -